TFA Therapeutics (RAJAF) Total Debt (2020 - 2025)

TFA Therapeutics has reported Total Debt for 6 years, with the latest figure at $4.5 million in Q4 2025.

• On a quarterly basis, Total Debt rose 3.08% year-over-year to $4.5 million in Q4 2025; TTM through Dec 2025 was $4.5 million, a 3.08% increase from a year earlier, with the FY2025 full-year figure at $4.5 million, up 3.08% from the prior year.
• Total Debt was $4.5 million for Q4 2025 at TFA Therapeutics, up from $4.3 million in the prior quarter.
• The five-year high for Total Debt was $4.5 million in Q4 2025, with the low at $414000.0 in Q3 2023.
• Average Total Debt over 5 years is $2.7 million, with a median of $3.1 million recorded in 2021.
• The sharpest annual moves came in 2022 and 2023: Total Debt slumped 76.13% in 2022, then surged 310.15% in 2023.
• Over 5 years, Total Debt stood at $3.1 million in 2021, then tumbled by 76.13% to $740382.0 in 2022, then soared by 310.15% to $3.0 million in 2023, then soared by 42.99% to $4.3 million in 2024, then advanced by 3.08% to $4.5 million in 2025.
• The last three Total Debt figures came in at $4.5 million (Q4 2025), $4.3 million (Q4 2024), and $3.0 million (Q4 2023), per Business Quant data.